论文部分内容阅读
溶血磷脂酸(lysophosphatidic acid,LPA)是一种对多种细胞具有不同生物学活性的磷脂介质,在组织中广泛存在。从细胞形态学改变到细胞功能的影响,LPA可产生如促进细胞增殖、迁移和耐药等生物学效应。如其他生物递质一样,LPA与细胞表面特定的G蛋白偶合受体(G protein-coupled receptoi,GPCR)发生交联作用,这些受体主要有Edg-2/LPA1、Edg-4/IPA2和Edg-7/LPA3等,它们被命名为内皮分化基因或溶血磷脂受体亚家族(endothelial differentiation gene or lysophospholipid receptor subfamily,Edg/LPAR subfamily)。LPA在体内外参与细胞增殖以及血管生成等病理生理过程,LPA代谢和Edg/LPA受体功能的异常与肿瘤的发生、发展相关,可能是肿瘤临床诊治的潜在靶点。本文阐述了LPA通过Edg/LPA受体介导在肿瘤发生和发展中的作用及其机制,并就其在胰腺癌临床诊治中的意义进行了评价。
Lysophosphatidic acid (LPA), a phospholipid mediator with diverse biological activity on a variety of cells, is widespread in tissues. From the morphological changes of cells to the function of cells, LPA can produce biological effects such as promoting cell proliferation, migration and drug resistance. Like other biological transmitters, LPA cross-links with G protein-coupled receptors (GPCRs) on the cell surface. These receptors are mainly Edg-2 / LPA1, Edg-4 / IPA2 and Edg -7 / LPA3, which are named endothelial differentiation gene or lysophospholipid receptor subfamily (Edg / LPAR subfamily). LPA is involved in the pathophysiological process of cell proliferation and angiogenesis both in vitro and in vivo, and the abnormality of LPA metabolism and Edg / LPA receptor function is related to the occurrence and development of tumor, which may be a potential target for the clinical diagnosis and treatment of tumors. This article describes the role of LPA in Edg / LPA receptor mediated tumorigenesis and progression and its mechanism, and its significance in the clinical diagnosis and treatment of pancreatic cancer were evaluated.